Patients must not have any history of locally advanced or metastatic cancer requiring systemic therapy within  years from randomization, with the exception of in-situ carcinomas and non-melanoma skin cancer; patients must have no previous primary lung cancer diagnosed concurrently or within the past  years
Prior malignancy within the past  years except non-melanoma skin cancer or other localized cancer treated with curative intent
Other active malignancy, except non-melanomic skin cancer
Diagnosed with or treated for cancer within the previous  years, other than breast cancer or non-melanoma carcinoma of the skin.
Active, concurrent malignancy requiring radiation, chemotherapy, or immunotherapy (excluding non-melanoma skin cancer, adjuvant hormonal therapy for breast cancer and hormonal treatment for castration sensitive prostate cancer).
Diagnosed with or received anti-cancer therapy for another primary malignancy within  years prior to entry (except for non-melanoma skin cancer or in situ cancers)
Individuals with a history of an active malignancy (other than the current lung cancer diagnosis) within the last  years (except non-melanoma skin cancer or a non-invasive/in situ cancer)
No history of other cancer (except non-melanoma skin cancer or in situ breast cancer or cervix cancer) unless the tumor was successfully treated with curative intent at least  years before trial entry
Currently active other malignancy other than non-melanoma skin cancer.
Women with previous history of cancer (including invasive or intra-ductal breast cancer) except for non-melanoma skin cancer.
EXCLUSION - PROCUREMENT: History of other cancer (except non-melanoma skin cancer or in situ breast cancer or cervix cancer) unless the tumor was successfully treated with curative intent at least  years before trial entry
Previous or concurrent malignancy other than non-melanoma skin cancer within  years of diagnosis of prostate cancer
Active, concurrent malignancy requiring radiation, chemotherapy, or immunotherapy (excluding non-melanoma skin cancer, adjuvant hormonal therapy for breast cancer and hormonal treatment for castration sensitive prostate cancer).
Known active invasive malignancy except for renal cell carcinoma and/or non-melanoma skin cancer
Any concurrent malignancy, except non-melanoma skin cancer
Prior malignancy requiring therapy within the last  months (excluding non-melanoma skin cancer); hormone therapy for prostate cancer or adjuvant endocrine therapy for breast cancer would not be excluded
Other active malignancy within the last  years (except for non-melanoma skin cancer, a non-invasive/in situ cancer, or indolent non metastatic Gleason  prostate cancer)
Active malignancy (with the exception of non-melanoma skin cancer), including relapse or progression of the underlying disease for which qualifying transplant was performed
Concomitant active malignancy that would be expected to require chemotherapy within  years of transplant (other than non-melanoma skin cancer)
Known second primary or prior malignancy diagnosed within  years of study start date (other than previously treated non-melanoma skin cancer)
Other concurrent cancer (with the exception of non-melanoma skin cancer and low-risk localized prostate cancer on active surveillance)
Previous or concurrent history of non-pancreatic malignancy except for non-melanoma skin cancer.
Unstable medical condition (e.g., another malignancy requiring treatment, malignant hypertension, poorly controlled diabetes, another cancer except for fully excised non-melanoma skin cancer)
Prior malignancy (except non melanoma skin cancer) within  years
Any known additional malignancy (with exception of non-melanoma skin cancer, in-situ breast cancer or a malignancy diagnosed >=  years ago and with no evidence of requiring active treatment)
Concurrent malignancy other than non-melanoma skin cancer
Active non-hematologic or lymphoid malignancy other than AML treated with immuno- or chemotherapy within the previous  months except active non-melanoma, non-invasive skin cancer will be allowed.
The subject has no other diagnosis of cancer (unless non-melanoma skin cancer, an early form of cervical cancer, or another cancer diagnosed >=  years previously) and currently has no evidence of active other malignancy (unless non-melanoma skin cancer or an early form of cervical cancer)
History of malignancy (other than non-melanoma skin cancer) within  years of enrollment
PROCUREMENT EXCLUSION CRITERA\r\n* Active infection requiring antibiotics\r\n* No history of other cancer (except non-melanoma skin cancer or in situ breast cancer or cervix cancer) unless the tumor was successfully treated with curative intent at least  years before trial entry
Patients must never have been diagnosed with any malignancy other than the current NSCLC, except for non-metastatic non-melanoma skin cancer, or cancer in situ of the cervix.
No history of unrelated (non-lymphomatous) neoplasms within past  years other than non-melanoma skin cancer or in-situ cancer
Concurrent cancer of any other type except skin cancer (excluding melanoma)
Known history of malignancy diagnosed within  years other than non-melanoma skin cancer.
Previous (within the past  years) or concurrent presence of other cancer, except non-melanoma skin cancer and in situ carcinomas.
Other active malignancy within the last  years (except for non-melanoma skin cancer, a non-invasive/in situ cancer, or indolent nonmetastatic Gleason  prostate cancer)
They must not have undergone treatment for any other form of cancer (aside from non-melanoma skin cancer) in the past five years
Prior or current non-gynecologic or non-breast malignancy within  years except non-melanoma skin cancer
Known concurrent malignancy (except for non-melanoma skin cancer)
Non-melanoma skin cancer;
History of non-prostate, primary, malignant cancer, except for non-melanoma skin cancer within previous five years
Diagnosed with or treated for cancer within the previous two years, other than breast cancer or non-melanoma carcinoma of the skin
No direct evidence of regional or distant metastases after appropriate staging studies; no synchronous primary or prior malignancy in past  years except non-melanoma skin cancer or in situ cancer
Concurrent untreated cancer excluding non-melanoma skin cancer
Have a concurrent active non-breast malignancy except for non-melanoma skin cancer
Participants has a prior history of malignancy, with the exception of non-melanoma skin cancer; participants with history of skin cancer must have  years elapse since that diagnosis, be in remission, and must not have received chemotherapy, immunotherapy, or radiation therapy
Prior malignancy (except non-melanoma skin cancer) within  months of study entry NOTE: Patients must be in complete remission from prior malignancy in order to be eligible to enter the study.
Patients with an active second malignancy with the exception of non-melanoma skin cancer
Concurrent malignancy (other than non-melanoma skin cancer) diagnosed within the past  years or any currently active malignancy
Prior malignancy (except non-melanoma skin cancer) within  years.
Patients who have had a history of non-cutaneous malignancy (other than non-melanoma skin cancer) in the previous  years are not eligible
Active second malignancy other than non-melanoma skin cancer
non-melanoma skin cancer
Concurrent malignancies other than non-melanoma skin cancer that require active ongoing treatment
Malignancy within last  years except non-melanoma skin cancer.
History of other malignancy within the past  years (except non-melanoma skin cancer)
Prior malignancy (except non-melanoma skin cancer) within  years
Malignancy other than nonmelanoma skin cancer
Had a malignancy, other than prostate or skin cancer (except malignant melanoma), within  years,
Patient has a concurrent diagnosis of a another cancer (other than non-melanoma skin cancer) and is in active treatment for it
Partner is also diagnosed with cancer (other than non-melanoma skin cancer) and is in active treatment for it
Partner cannot have cancer diagnosis (other than non-melanoma skin cancer) and be currently receiving treatment
Personal diagnosis of any cancer, other than non-melanoma skin cancer
Any other cancer present within the last  years (other than gynecologic cancer under study and non-melanoma skin cancer)
History of any other malignancy treated within the past  years (other than non-melanoma skin cancer)
History of any other malignancy treated within the past  years (other than non-melanoma skin cancer)
No prior history of malignancy other than non-melanoma skin cancer (patient)
Prior history of malignancy other than non-melanoma skin cancer (patient)
Have a concurrent active non-breast malignancy except for non-melanoma skin cancer
Past history of any cancer other than non-melanoma skin cancer
Not have been treated for other cancer (except non-melanoma skin cancer) in the past  years
Participants may have a personal history of non-ovarian malignancy, but must: a) be without evidence of disease at enrollment b) remain premenopausal c) have completed treatment (including surgery, chemotherapy, radiotherapy or hormonal therapy) >  months prior to enrollment (other than non-melanoma skin cancer)
Women with a history of any cancer within the last  years, except for non-melanoma skin cancer; history of breast cancer must be at least >  years from diagnosis
History of cancer (except for non-melanoma skin cancer)
Individuals with any history of cancer other than non-melanoma skin cancer
Have received chemotherapy and/or radiation for any malignancy (excluding non-melanoma skin cancer and cancers confined to organs with removal as only treatment) in the past  years; ongoing adjuvant hormonal therapy for breast cancer is allowed
Evidence of other cancer(s) (excluding non-melanoma skin cancer) within last  years
Other chronic disease likely to limit lifespan to less than - years, including any cancer requiring treatment in past  years except non-melanoma skin cancer
New cancer diagnosis in the last six months (with the exception of non-melanoma skin cancer)
Subjects with current or previous malignancy other than prostate or non-melanoma skin cancer;
Any type of active invasive cancer (excluding breast and non-melanoma skin cancer) within the preceding  months
Women who have been treated with chemotherapy for prior malignant disease or currently have an untreated malignancy other than non-melanoma skin cancer
Diagnosis of any cancer (except non-melanoma skin cancer)
With a history of another cancer, except for non-melanoma skin cancer, as per medical records or patient report
Prior history of any other malignancy within last  years, other than non-melanoma skin carcinoma
Concurrent malignancy other than non-melanoma skin cancer
Any malignancy other than non-melanoma cell skin cancer, unless no evidence of disease for a minimum of  years
Patient cannot have received treatment for any malignancy, with the exception of non-melanoma skin cancer, in the past  years
No prior treatment within  years for another cancer, including chemotherapy, surgery (except for diagnostic biopsy), radiation therapy, hormonal therapy or investigational agents, unless curative treatment of non-melanoma skin cancer or in situ cancer
Any previous diagnosis of cancer except for non-melanoma skin cancer
Patients who have had a history of non-cutaneous malignancy in the previous  years are not eligible; exception: patients with history of non-melanoma skin cancer are eligible
History of any cancer, other than non-melanoma skin cancer (Arm )
Any malignancy other than non-melanoma cell skin cancer, unless no evidence of disease for a minimum of  years
